Laurus Labs Ltd posts Q2 FY27 net profit of ₹441 crore, up 126%, and proposes a US$3.75 million investment for 60% of Canada’s Galenvs Sciences.
- Revenue rose 33% year on year to ₹2,206 crore.
- EBITDA was ₹762 crore; margin expanded to 34.5% from 26.0% a year earlier.
- The proposed stake acquisition, subject to due diligence, is intended to expand oligonucleotide capabilities.
- Q2 FY27 results are unaudited.